Additionally, the reach of precision oncology has been extended to early-stage disease as osimertinib, a third-generation EGFR-TKI, is now approved for adjuvant therapy for resectable early-stage EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.